Submit your Center of Excellence Application today!

Read More


Feb 27, 2020

Novartis launches review on safety of Beovu eye medication

by: Admin

ZURICH (Reuters) – Novartis launched an external review on the safety of its Beovu blindness drug after the American Society of Retina Specialists (ASRS) expressed concern.
Shares of the Swiss drug manufacturer fell almost 3% in the first operations after ASRS informed its members about the drug, a replacement for Novartis sales success, Lucentis.

Since the approval of Beovu last October, ASRS has received reports of 14 cases of vasculitis, an inflammation of the blood vessels, of which 11 were designated occlusive retinal vasculitis, an inflammatory eye condition that threatens vision.
Novartis said he was aware of the recently reported adverse effects of the drug, adding that “it supports the safety and efficacy of Beovu.”

“In addition to our own internal assessment, we have hired an external safety review committee (SRC) to further evaluate these post-marketing cases. We will continue to share details as they become available,” the company said.

About 46,000 Beovu injections have been administered so far, Novartis said. The US Food and Drug Administration. UU. I was aware of the review, while the company now informs other health authorities.

Read more:

Source: News Dio

Newsletter Sign-up

  • This field is for validation purposes and should be left unchanged.